Latest Conference Coverage

Levels of GFAP Higher in NMOSD, Suggesting It May Serve as a Biomarker

A subset group of inebilizumab-treated patients who did not have adjudicated attacks displayed more than a 2-fold increase in serum CSF glial fibrillary acidic protein from baseline, implying GFAP may serve as a biomarker.

Pediatric MS Disease Activity May Increase Upon Menarche

Findings from a study of more than 500 girls with multiple sclerosis suggest that first menstruation and the onset of puberty may be a time of increased disease activity in pediatric MS.

CMSC 2020 Day 2: Patricia Bobryk, MHS, PT, MSCS, ATP, on Rehab in MS: That Was Then, This Is Now

Patricia Bobryk, MHS, PT, MSCS, ATP, presents her lecture titled, "Rehabilitation in MS: That Was Then, This Is Now" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 2: Brenda Banwell, MD, on Current Perspectives of Pediatric MS Care and Research

Brenda Banwell, MD, presents her lecture titled, "Current Perspectives of Pediatric MS Care and Research" as part of the 2020 CMSC Virtual Annual Meeting.

Satralizumab Shows Safe Profile in Patients With NMOSD

Data from the overall satralizumab treatment period, which expanded on the double-blind periods by adding new data from the ongoing open-label extension periods, were consistent with the double-blind period results.

CMSC 2020 Day 2: Mona Bostick, RDN, LDN, on the Importance of Nutritional Health in Patients With MS

CMSC 2020 Day 2: Anthony Feinstein, MPhil, PhD, on Diagnosing and Treating Depression in MS

Anthony Feinstein, MPhil, PhD, FRCP, presents his lecture titled, "Depression and MS: Diagnosing and Treating" as part of the 2020 CMSC Virtual Annual Meeting.

MSProDiscuss Tool Is Usable and Useful in MS Clinical Practice

A real-world survey of more than 300 health care practitioners suggests that the MSProDiscuss tool offers a useful tool for the physician-patient discussion on multiple sclerosis disease progression.

Natalizumab Provides Superior 'Feel Good' Experience in MS Over Other Treatments

Increases in physical, emotional, and cognitive functioning were more common in patients receiving natalizumab than in patients receiving other disease modifying therapies.

Siponimod Reduces Risk of Disability Progression Regardless of Prior Relapses in MS

The Novartis agent showed benefit in patients who had multiple sclerosis both with and without relapses.

CMSC 2020 Day 1: Patricia Melville, Marijean Buhse, PhD, on Comorbidities and Critical Thinking About DMTs and Vaccines

Patricia Melville, NP-C, MSCN, and Marijean Buhse, PhD, NP-C, MSCN, present their lecture titled, "Comorbidities and MS: Critical Thinking About DMTs and Vaccines" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 1: Amy Sullivan, PsyD, ABPP, on Science, Art, and Practice of Behavioral Medicine in MS

Amy Sullivan, PsyD, ABPP, presents her lecture titled, "Science, Art, and Practice of Behavioral Medicine" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 1: Brian Weinshenker, MD, on Emerging Treatment Options for NMOSD

Brian Weinshenker, MD presents his lecture titled, "Neuromyelitis Optica Spectrum Disorders: Emerging Treatment Options" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 1: Patricia Coyle, MD on Diagnosis, Clinical Course, and Long-Term Management of Progressive MS

Patricia Coyle, MD, delivers her lecture titled, "Progressive MS: Diagnosis, Clinical Course and Long-Term Management" as part of the 2020 CMSC Virtual Annual Meeting.

Evobrutinib Shows Long-Term Efficacy and Safety in Phase 2 Study

Evobrutinib, a highly selective BTK inhibitor for the treatment of relapsing multiple sclerosis, showed long-term safety and success in reducing annualized relapse rates.

Ocrelizumab Has Similar Effects in MS With Shorter Infusion Time

The Genentech agent, which is approved for patients with relapsing-remitting multiple sclerosis, showed no new safety signals in a comparison between conventional and shorter infusion times.

Ofatumumab Increases NEDA-3 Likelihood in MS Compared With Teriflunomide

Novartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of disease activity status by more than 3-fold in the first year and more than 8-fold in the second year.

The Importance of Interdisciplinary Care in MS

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic detailed the need to incorporate interdisciplinary care and behavioral medicine in commonplace MS practice.

Mark Freedman, MD: An Update on Stem Cell Research in MS

The director of the multiple sclerosis research unit at Ottawa Hospital discussed stem cell therapies being explored in multiple sclerosis, and which patients may be eligible for these treatments.

Second Dose of Ubrogepant Is Safe and Effective in Acute Migraine

The study author, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of a pooled analysis of the ACHIEVE I and II studies of ubrogepant.

Brenda Banwell, MD: Current Perspectives on Pediatric MS Care and Research

The chief of the Division of Neurology at Children’s Hospital of Philadelphia spoke to the need for clinical trial evidence and research for the pediatric MS population.

Andrew Blumenfeld, MD: Long-Term OnabotulimuntoxinA Use in the COMPEL Study

The director of the Headache Center of Southern California discussed the findings of the study, as well as what these data might suggest about how onabotulinumtoxinA fits into the shifting landscape of chronic migraine care.

Amy Sullivan, PsyD, ABPP: Interdisciplinary Care in MS

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of interdisciplinary care and ways it can be incorporated for patients with multiple sclerosis.

Ofatumumab Shines in Pooled Comparative Analysis in Relapsing Multiple Sclerosis

The neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how the agent might fit into the treatment landscape if its sBLA is approved by the FDA later this year.

Nusinersen Shows Efficacy in Infantile- and Late-Onset Spinal Muscular Atrophy

The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated a newfound durability in patients with later-onset spinal muscular atrophy.

Steve Chung, MD: Cannabidiol in Tuberous Sclerosis Complex

The neurologist at Banner-University Medicine Neuroscience Institute offered his perspective on data from an open-label safety assessment of cannabidiol (Epidiolex) in the treatment of tuberous sclerosis complex.

Jessica Ailani, MD: Optional Second Dose of Ubrogepant in Acute Migraine

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of an analysis from the ACHIEVE studies of ubrogepant.

BAN2401 Linked to Persistent Negative Amyloid PET in Alzheimer Disease

Despite patients being off treatment for an average of 23 months, patients treated with Eisai’s BAN2401 remained amyloid PET negative in an open-label extension preliminary analysis.

Eteplirsen Slows Pulmonary Decline in Duchenne Muscular Dystrophy

The FDA-approved treatment was associated with a clinically meaningful delay in needing continuous ventilation among patients with Duchenne muscular dystrophy.

Nina Riggins, MD, PhD: The Effect of Dihydroergotamine Infusion Rates

The headache specialist at UCSF discussed the findings of a retrospective assessment of the impact of the infusion rate of dihydroergotamine (DHE) on inpatient treatment outcomes.